


Hikal Limited

9MFY19: Strong Growth Continues

- ✓ Sales of Rs. 1,132 Crore; Growth of 24%
- ✓ EBITDA of Rs. 214 Crore; Growth of 26%
- ✓ PAT of Rs. 70 Crore; Growth of 34%
- ✓ Declared Interim Dividend of 30%

Mumbai, February 1st, 2019: Hikal Ltd, a preferred long-term partner for leading global life sciences companies, announced its financial results for the quarter ended 31st December, 2018.

Highlights for 9 months ended 31st December, 2018




Performance highlights for the 9 months ended 31st December, 2018

- **Sales up 24% to Rs. 1,132 crore** as compared to Rs. 910 crore in the corresponding period of the previous year
- **EBITDA up 26% to Rs. 214 crore** as compared to Rs. 170 crore in the corresponding period of the previous year
- **PAT up 34% to Rs. 70 crore** as compared to Rs. 52 crore in the corresponding period of the previous year

Segmental Performance for the 9 months ended 31st December, 2018

- **Crop Protection sales up 22% to Rs. 452 crore** as compared to Rs. 372 crore in the corresponding period of the previous year
- **Pharmaceutical sales up 26% to Rs. 680 crore** as compared to Rs. 538 crore in the corresponding period of the previous year

Highlights for quarter ended 31st December, 2018



Performance highlights for the quarter ended 31st December, 2018

- **Sales up 17% to Rs. 412 crore** as compared to Rs. 351 crore in the corresponding period of the previous year
- **EBITDA up 17% to Rs. 78 crore** as compared to Rs. 67 crore in the corresponding period of the previous year
- **PAT up 26% to Rs. 29 crore** as compared to Rs. 23 crore in the corresponding period of the previous year

Segmental Performance for the quarter ended 31st December, 2018

- **Crop Protection sales up 15% to Rs. 160 crore** as compared to Rs. 139 crore in the corresponding period of the previous year
- **Pharmaceutical sales up 19% to Rs. 252 crore** as compared to Rs. 212 crore in the corresponding period of the previous year

Commenting on the results, Jai Hiremath, Chairman & Managing Director, Hikal Ltd. said,

“We continue our strong growth with Revenues crossing Rs. 1,100 crores for the first 9 months period of a financial year with an EBITDA margin of 19%.

Both our businesses have been performing well with the Pharmaceutical division registering a growth of 26% and Crop Protection division registering a growth of 22%. The growth for the current year is driven by higher volumes, new launches and an improved product mix.

We are undertaking significant capital investment in both our businesses to meet the growing demand for existing products and new product launches under various stages of commercialisation. We are also debottlenecking plants in both our divisions to meet the increased demand.

The Board of Directors has declared interim dividend of Re. 0.60 per share (Face Value of Rs. 2 per share).

In view of the strong performance in our business, we are very positive that the current growth momentum will continue in the coming years.”



About Hikal Limited

Hikal is a reliable long-term partner to companies in the Pharmaceuticals, Crop Protection, and Specialty Chemicals industry. The company is in the business of supplying research services, active ingredients and intermediates, manufactured using stringent global quality standards, for its global customers. Hikal's advanced manufacturing facilities have been inspected and approved by leading multinational companies in the Crop protection and Pharmaceutical sectors. The Crop protection facilities are located at Taloja and Mahad (Maharashtra). Hikal's R&T facilities are located at Pune. The Pharmaceutical manufacturing facilities are situated in Jigani (Bengaluru) and Panoli (Gujarat). Hikal is the first Indian life-sciences company to receive the Responsible Care® certification governed by the International Council of Chemical Associations (ICCA).

Safe Harbor Statement

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.

For further information, please contact

Company :

Hikal Limited

CIN: L24200MH1988PTC048028

Mr. Anish Swadi
anish_swadi@hikal.com

www.hikal.com

Investor Relations Advisors :

Strategic Growth Advisors Pvt. Ltd.

CIN: U74140MH2010PTC204285

Ms. Payal Dave / Mr. Jigar Kavaiya
payal.dave@sgapl.net / jigar.kavaiya@sgapl.net
+91 9819916314 / +91 9920602034

www.sgapl.net